Modernavs.Vertex Pharmaceuticals
MRNA vs VRTX · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Vertex Pharmaceuticals is about 1.6× larger than Moderna by market cap; year to date, Moderna leads (+566.3% vs +11.5%).
Side by side
| MRNA | VRTX | |
|---|---|---|
| Market cap | $78.6B | $128B |
| Price | $197.00 | $503.25 |
| Today | +0.3% | −0.5% |
| Return YTD | +566.3% | +11.5% |
| Return 1Y | +618.7% | +23.2% |
| Since June 26, 2026 | +192.8% | +2.4% |
| P/E | — | 29.1 |
| P/S | 35.3 | 10.2 |
| P/B | 11.6 | 6.3 |
Data as of 2026-10-08 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
ModernaMRNA
Built on mRNA, the technology behind its covid vaccine. The pipeline pushes the same platform into further vaccines and into oncology.
Full MRNA profile →Vertex PharmaceuticalsVRTX
Cystic fibrosis medicines carry the business. The newer work sits in pain treatment and in cell and gene therapy, where Casgevy belongs.
Full VRTX profile →More MRNA & VRTX comparisons
Other head-to-heads in the Biotech & innovation segment.